Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs

Reuters01-12

Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Extends Cash Runway Into 2029 and Advances Clinical Programs

Beam Therapeutics Inc. announced continued progress in its precision genetic medicines programs, highlighting advancements in its liver-targeted genetic disease and hematology franchises. The company reported alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) based on biomarker endpoints. Beam expects to submit a Biologics License Application (BLA) for risto-cel (formerly BEAM-101) as early as the end of 2026. The company also plans to expand its liver-targeted genetic disease franchise with a new program announcement in the first half of 2026. Beam ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities, and projects its operating runway to extend into 2029, supporting the anticipated launch of risto-cel in sickle cell disease $(SCD)$ and the execution of the BEAM-302 pivotal development plan in AATD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623450) on January 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602682295?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 06:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602682295","market":"us","top_or_hot":-1,"title":"Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Extends Cash Runway Into 2029 and Advances Clinical Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Beam Therapeutics Inc. announced continued progress in its precision genetic medicines programs, highlighting advancements in its liver-targeted genetic disease and hematology franchises. The company reported alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) based on biomarker endpoints. Beam expects to submit a Biologics License Application (BLA) for risto-cel (formerly BEAM-101) as early as the end of 2026. The company also plans to expand its liver-targeted genetic disease franchise with a new program announcement in the first half of 2026. Beam ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities, and projects its operating runway to extend into 2029, supporting the anticipated launch of risto-cel in sickle cell disease <a href=\"https://laohu8.com/S/SCD\">$(SCD)$</a> and the execution of the BEAM-302 pivotal development plan in AATD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623450) on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Extends Cash Runway Into 2029 and Advances Clinical Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Beam Therapeutics Inc. announced continued progress in its precision genetic medicines programs, highlighting advancements in its liver-targeted genetic disease and hematology franchises. The company reported alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) based on biomarker endpoints. Beam expects to submit a Biologics License Application (BLA) for risto-cel (formerly BEAM-101) as early as the end of 2026. The company also plans to expand its liver-targeted genetic disease franchise with a new program announcement in the first half of 2026. Beam ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities, and projects its operating runway to extend into 2029, supporting the anticipated launch of risto-cel in sickle cell disease <a href=\"https://laohu8.com/S/SCD\">$(SCD)$</a> and the execution of the BEAM-302 pivotal development plan in AATD.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623450) on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL3KJXWN:1","article_id":"2602682295","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602682295","pubTimestamp":1768168830,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Beam Therapeutics Inc. announced continued progress in its precision genetic medicines programs, highlighting advancements in its liver-targeted genetic disease and hematology franchises. The company reported alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency  based on biomarker endpoints. Beam expects to submit a Biologics License Application  for risto-cel  as early as the end of 2026. The company also plans to expand its liver-targeted genetic disease franchise with a new program announcement in the first half of 2026. Beam ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities, and projects its operating runway to extend into 2029, supporting the anticipated launch of risto-cel in sickle cell disease  and the execution of the BEAM-302 pivotal development plan in AATD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4535":"淡马锡持仓","BEAM":"Beam Therapeutics, Inc.","BK4505":"高瓴资本持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4611":"AI医疗"},"translate_title":"Beam Therapeutics将现金跑道延长至2029年并推进临床项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9,"NDAQ":0.9},"content_text":"Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs\n    \n\n        Beam Therapeutics Inc. announced continued progress in its precision genetic medicines programs, highlighting advancements in its liver-targeted genetic disease and hematology franchises. The company reported alignment with the U.S. FDA on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) based on biomarker endpoints. Beam expects to submit a Biologics License Application (BLA) for risto-cel (formerly BEAM-101) as early as the end of 2026. The company also plans to expand its liver-targeted genetic disease franchise with a new program announcement in the first half of 2026. Beam ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities, and projects its operating runway to extend into 2029, supporting the anticipated launch of risto-cel in sickle cell disease $(SCD)$ and the execution of the BEAM-302 pivotal development plan in AATD.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623450) on January 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602682295","isCrawlerRequest":true}